A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia

NCT02227693 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombocytopenia Associated With Chronic Liver Disease

Interventions

DRUG: avatrombopag
DRUG: Placebo

Sponsor

Eisai Co., Ltd.